Evidence map›Paper›PMID 41117419›Full record

ArticleACS applied materials & interfaces2025

Preparation and Antiviral Activity of La

Ryuju Kiribayashi, Kayano Sunada, Toshihiro Isobe, Keiichi Kobayashi, Takeshi Nagai, Hitoshi Ishiguro, Yasuhide Mochizuki, Akira Nakajima

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ryuju KiribayashiDepartment of Materials Science and Engineering, School of Materials and Chemical Technology, Institute of Science Tokyo, 2-12-1 O-okayama, Meguro, Tokyo 152-8550, Japan.
Kayano SunadaLife Science Technology Project, Kanagawa Institute of Industrial Science and Technology, LiSE4c-1, 3-25-13 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan.
Toshihiro IsobeDepartment of Materials Science and Engineering, School of Materials and Chemical Technology, Institute of Science Tokyo, 2-12-1 O-okayama, Meguro, Tokyo 152-8550, Japan.
Keiichi KobayashiLife Science Technology Project, Kanagawa Institute of Industrial Science and Technology, LiSE4c-1, 3-25-13 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan.
Takeshi NagaiLife Science Technology Project, Kanagawa Institute of Industrial Science and Technology, LiSE4c-1, 3-25-13 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan.
Hitoshi IshiguroLife Science Technology Project, Kanagawa Institute of Industrial Science and Technology, LiSE4c-1, 3-25-13 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan.
Yasuhide MochizukiDepartment of Materials Science and Engineering, School of Materials and Chemical Technology, Institute of Science Tokyo, 2-12-1 O-okayama, Meguro, Tokyo 152-8550, Japan.ORCID 0000-0002-8292-7736
Akira NakajimaDepartment of Materials Science and Engineering, School of Materials and Chemical Technology, Institute of Science Tokyo, 2-12-1 O-okayama, Meguro, Tokyo 152-8550, Japan.ORCID 0000-0003-0056-9283

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copper oxide is a representative inorganic antiviral material. However, the highly active Cu

Indexed as

Antiviral AgentsCopperLanthanumOxidesYttriumAntiviral AgentsCoppercupric oxidecuprous oxideLanthanumOxidesyttriaYttriumcopperfirst-principles calculationssurface formal chargeternary oxidevirus

Identifiers

PMID41117419
PMCPMC12616611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.